NCT05702671

Kenota 1 CWS Method Comparison Validation Study

Clinical Validation Study of Point of Care Kenota 1 System and Total Immunoglobulin E Test Kit Using the CWS Method Comparison Validation Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 411 (actual)
• Sponsor: Kenota Inc. · Industry
• Sex: All
• Age: 80 Years
• Healthy volunteers: Accepted

Summary

The goal of this Method Comparison Study is to compare total IgE results obtained from at least 360 subjects aged less than 80 years old using four different testing arms comprising three types of samples and two testing methods. The main questions it aims to answer are: * Are the Kenota 1 Devices easy to use by untrained operators at a clinic environment? * Do tIgE results provided by the Kenota 1 Devices match the results provided by the FDA-cleared Phadia ImmunoCAP System? Subjects will be asked to donate two fingerstick whole blood samples and one venous blood draw.

Detailed description

The Method Comparison Study will compare total IgE results obtained from at least 360 subjects aged less than 80 years old using four different testing arms. comprising three types of samples and two testing methods. Arm (A): Fresh fingerstick whole blood will be collected and tested on Kenota 1 Devices at three CLIA-Waived sites (CWSs). Arm (B): Venous plasma will be collected at the CWSs and tested on Kenota 1 Devices at the central lab site. Arm (C): Venous plasma will be collected at the CWSs and tested on Phadia instruments (ImmunoCAP) at the central lab site. Arm (D): Venous whole blood will be collected at the CWSs and tested on Kenota 1 Devices at the central lab site. The first method for this study is the Kenota 1 System, which will be used across Three (3) U.S. CWSs. At each CWS, 120 subjects will be recruited and will be asked to donate fingerstick blood and venous blood. Three (3) untrained operators at each site will be running the freshly collected fingerstick blood samples on the Kenota 1 Devices provided at the site (Testing Arm A). Site operators will also process and store the collected venous blood and venous plasma samples as instructed, and ship them to the central lab for further testing. The second method for this study involves testing at a Central US Laboratory as a CLIA-regulated laboratory. At the central lab, at least one trained lab operator will run frozen venous plasma (testing Arm B) and frozen venous whole blood (testing Arm D) collected from all subjects using the Kenota 1 Devices provided at the central lab. As the comparator method, one lab operator will run a second set of frozen plasma samples collected from all subjects on the Phadia ImmunoCAP System (testing Arm C). The Method Comparison Validation Study is expected to be completed within two months and will be run in conjunction with the Multi-Site Reproducibility Validation Study. All testing will include a daily External Control session on each device used, ensuring the devices are performing as expected.

Conditions

• Allergy
• Immunoglobulin E-Mediated Allergic Disorder

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Total Immunoglobulin E, Obtained From Fingerstick Sample	The Kenota 1 System is intended to be a specialized tool in a professional allergist setting. It will help streamline the patient testing process by bringing quantitative, minimally invasive fingerstick IgE blood testing to the allergy clinic.

Timeline

• Start date: 2023-01-27
• Primary completion: 2023-04-07
• Completion: 2023-04-07
• First posted: 2023-01-27
• Last updated: 2023-05-06

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated device study